common stock, $0.01 par value
- Symbol
- KRMD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
KORU Medical Systems, Inc.
KRMDNASDAQEQUITYCurrent
Results of Operations and Financial Condition
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. (a) Public Announcement or Release. On January 12, 2026, KORU Medical Systems, Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fiscal quarter and year ended December 31, 2025. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60® and FreedomEDGE® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
Current securities
Historical securities (1)
Registered securities in this filing
KORU Medical Systems, Inc. · 8-K · Filed 2026-01-12
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
(a) Public Announcement or Release.
On January 12, 2026, KORU Medical Systems, Inc. (the
“Company”) issued a press release announcing certain preliminary financial results for the fiscal quarter and year ended December
31, 2025. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The preliminary financial
results included in the press release are based on the Company’s current estimate of its results for the fiscal quarter and
year ended December 31, 2025, and remain subject to change based on the completion of closing and review procedures.
The information contained in this Item 2.02 of the
Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any
filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as
expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99 2 ex_99-1.htm PRESS RELEASE, DATED JANUARY 12, 2026 EXHIBIT 99.1 KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow MAHWAH, NJ - January 12, 2026 - KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9 million, representing growth of 23% over the prior year period Preliminary, unaudited full year 2025 net revenues expected to be $41.1 million, representing growth of 22% over the prior year Ending cash balance of $8.9 million, representing positive cash flow in the fourth quarter and positive cash flow from operations for the full year. “We delivered strong fourth quarter results and enter 2026 with solid momentum, driven by continued strength in our core immunoglobulin…
Open exhibit ↗